Lakewood Capital

Lakewood Amedex is a clinical-stage biotechnology company based in Sarasota, Florida, specializing in the development of novel anti-infective therapies. The company's primary platform involves a new class of synthetic, broad-spectrum antimicrobials known as Bisphosphocins, which are designed to rapidly kill bacteria by disrupting their cell membranes without inducing resistance. Its lead product candidate, Nu-3, has demonstrated efficacy in Phase 2 clinical trials for the treatment of infected diabetic foot ulcers. Additionally, Lakewood Amedex is advancing a proprietary "nanomer" RNA-silencing technology (nSNA) aimed at treating viral infections and other genetic disorders by targeting specific mRNA sequences. The company's approach addresses the critical global need for new treatments for antibiotic-resistant infections and complex viral diseases.